Relationship between haematological markers and patological complete response to neoadjuvant treatment in locally advanced rectal cancer
DOI:
https://doi.org/10.19230/jonnpr.3754Keywords:
rectum, cancer, haematological markersAbstract
Introduction. Multiple haematological markers of inflammation might be related with poor prognosis in oncological patients.
Purpose. This study evaluated whether changes of haematological markers before and after chemo- radiotherapy treatment in rectal cancer might be associated to pathological complete response.
Material and Methods. Medical records of 140 patients with rectal cancer who received neoadjuvant radiotherapy followed by surgical resection were retrospectively review. Complete bloods counts (CBC) was measured days before and after period of RT. We assessed white blood cells count (WBC), hemoglobin levels (Hb), neutrophils count, lymphocytes count, monocytes count, neutrophil-to-lymphocye ratio (NLR), platelet- to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR).
Results. The overall rate of pCR was 17,5%. Hematological markers had a statistically significant decrease after CRT treatment (p<0,05), however in our analysis they do not predict complete pathological response.
Conclusion. Haematological markers before and after neoadjuvant treatment do not predict tumor responses in this study. However, a larger sample can show statistically significant results, especially in monocytes ratio.
Downloads
References
Urrejola G. I, Bambs C. E., Espinoza M. A. Et al. Un índice neutrófilo/linfocito elevado se asocia a peor pronóstico en cáncer de colon etapa II resecado. Rev. Med Chile 2013; 131: 602-608.
Lee J H, Jeong J U, Kim S H, et al. Nadir/pre-chemoradiotherapy ratio of White blood-cell count can predict tumor response and recurrence-free survival in locally advanced rectal cancer: a multi-institutional analysis. Interntional Journal of Colorectal Disease. https:/doi.org/10.1007/s00384-018-3174-8.
Braun L H, Baumann D, Zwirner K, et al. Neutrophil-to-lymphocyte ratio in rectal cancer-Novel biomarker of tumor immunogenicity during radiotherapy or confounding variable? Int. J. Mol. Sci 2019, 20, 2448.
Jeon B H, Shin U S, Moon S M, et al. Neutrophil to lymphocyte ratio: a predictive marker for treatment outcomes in patients with rectal cancer who underwent neoadjuvant chemoradiation followed by surgery. Ann Coloproctol 2019;35 (2): 100-106
Haram, A.; Boland, M.R; Kelly, M.E; Bolger, J.C; Waldron, R.M, Kerin, M.J. The prognostic value of neutrophil-to- lymphocyte ratio in colorectal cancer: A systematic review. J. Surg. Oncol. 2017, 115, 470-479.
Clarke TL, White DA, Osborne ME et al. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers. Ann R Coll Surg Engl 2017; 99: 373-377
Forssell J, Oberg A, Henriksson ML, et al. High macrophague infiltration along the tumor front correlatos with improved survival in colon cancer. Clin Cancer Res 2007;13:1472-9
Wu Q-B, Wang M, Hu T, et al. Prognostic role of the lymphocyte-to-monocyte ratio in patients undergoing resection for nonmetastatic rectal cancer. Medicine (2016) 95:44 (e4945)
Lee J H, Song C, Kang S-B et al. Predicting pathological complete regression with haematological markers Turing neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Anticancer research 38:6905-6910 (2018)
Lee Y J, Lee S B, Beak S K, et al. Temporal changes in immune cell composition and cytokines in response to chemoradiation in rectal cancer. Scientific reports (2018) 8:7565
Kim, I.Y; You, S.H.; Kim, Y.W. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 2014,14, 94.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
